Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)

Alberto L Epstein; Cornelia Haag-Molkenteller

doi:10.1016/j.cell.2023.07.031

Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)

Cell. 2023 Aug 17;186(17):3523-3523.e1. doi: 10.1016/j.cell.2023.07.031.

Authors

Alberto L Epstein¹, Cornelia Haag-Molkenteller²

Affiliations

¹ EG427 Paris, France. Electronic address: alberto@eg427.com.
² EG427 Paris, France. Electronic address: cornelia@eg427.com.

PMID: 37595560
DOI: 10.1016/j.cell.2023.07.031

Abstract

The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.

MeSH terms

Epidermolysis Bullosa Dystrophica* / genetics
Epidermolysis Bullosa Dystrophica* / therapy
Genetic Therapy*
Herpesvirus 1, Human / genetics
Humans